Patent estate

Celltrion — Patent Portfolio

6 drugs with active patents · 0 active patents · 0 expired · 6 biologics with BPCIA exclusivity

AI-enriched 0/0 patents with grounded plain-English summaries · sourced from FDA Orange Book + Purple Book · updated 2026-05-18

Loss of exclusivity calendar · next 12 years

Drugs facing US patent or BPCIA biologic exclusivity loss per year. Click any year to see the broader cliff calendar for the industry.

2 2030 1 2034 1 2035 1 2036 1 2037

Patent estate by drug

AVTOZMA (TOCILIZUMAB-ANOH)

🧬 BPCIA biologic exclusivity to 2037-01-24

HERZUMA (TRASTUZUMAB-PKRB)

🧬 BPCIA biologic exclusivity to 2030-12-14

STEQEYMA (USTEKINUMAB-STBA)

🧬 BPCIA biologic exclusivity to 2036-12-17

TRUXIMA (RITUXIMAB-ABBS)

🧬 BPCIA biologic exclusivity to 2030-11-28

VEGZELMA (BEVACIZUMAB-ADCD)

🧬 BPCIA biologic exclusivity to 2034-09-27

YUFLYMA (ADALIMUMAB-AATY)

🧬 BPCIA biologic exclusivity to 2035-05-23

Sources

  • FDA Orange Book — small-molecule patents listed against approved NDAs.
  • FDA Purple Book — biologic BPCIA 12-year reference product exclusivity.
  • USPTO Patent Public Search — title, abstract, claim text grounding.
  • AI summaries generated by Drug Landscape, grounded in source claim text.

Patent term extensions (PTR, SPC, pediatric exclusivity) may shift effective expiry. Not legal advice.

Track Celltrion's patent estate

Daily alerts when vulnerability scores shift, patents expire, or IPRs are filed. Free tier: 3 watches. Pro tier (£199/mo): 50 watches + daily AI Pharma IP Brief.

↓ CSV export